Li T, Tamada K, Abe K, Tada H, Onoe Y, Tatsugami K, Harada M, Kubo C, Nomoto K
Department of Immunology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
Immunopharmacology. 1999 Jun;43(1):11-21. doi: 10.1016/s0162-3109(99)00034-x.
We previously reported that restraint stress impairs the antitumor immune responses through its suppressive effect on the Th1-type cytokine production from CD4+ T cells. In this study, we investigated a potential of Hochu-ekki-to (TJ-41:Bu-Zhong-Yi-Qi-Tang) to restore stress-induced immunosuppression. The oral administration of TJ-41 was able to improve a decreased cellularity in the lymph node and spleen and to improve an inhibition of tumor-specific Th1-type cytokine production, both of which were induced by repeated restraint stress in tumor-bearing mice. The oral administration of TJ-41 also induced a partial recovery of the antitumor cytolytic activity in the stress-burdened tumor-bearing mice. More importantly, the growth of tumors in stress-burdened preimmunized mice was obviously inhibited by TJ-41, and resulted in tumor-free state in 75% of the mice. Regarding the mechanisms by which TJ-41 restored the antitumor responses in stress-burdened mice, we found that the serum levels of corticosterone and interleukin-12 were normalized by TJ-41. In addition, the expression of CD80 and CD86, which both decreased in the stress-burdened mice, was restored to the normal level by TJ-41. Taken together, our results indicate that the oral administration of TJ-41 is able to restore the antitumor T cell responses in stress-burdened tumor-bearing mice by normalizing the serum corticosterone, interleukin-12 and the expression of costimulatory molecules.
我们之前报道过,束缚应激通过抑制CD4+ T细胞产生Th1型细胞因子来损害抗肿瘤免疫反应。在本研究中,我们调查了补中益气汤(TJ-41)恢复应激诱导的免疫抑制的潜力。给荷瘤小鼠反复施加束缚应激会导致其淋巴结和脾脏细胞数量减少以及肿瘤特异性Th1型细胞因子产生受到抑制,而口服TJ-41能够改善这些情况。口服TJ-41还能使承受应激的荷瘤小鼠的抗肿瘤细胞溶解活性部分恢复。更重要的是,TJ-41明显抑制了承受应激的预免疫小鼠体内肿瘤的生长,使75%的小鼠达到无瘤状态。关于TJ-41恢复承受应激小鼠抗肿瘤反应的机制,我们发现TJ-41使皮质酮和白细胞介素-12的血清水平恢复正常。此外,承受应激的小鼠体内均降低的CD80和CD86的表达也通过TJ-41恢复到了正常水平。综上所述,我们的结果表明,口服TJ-41能够通过使血清皮质酮、白细胞介素-12以及共刺激分子的表达恢复正常,来恢复承受应激的荷瘤小鼠的抗肿瘤T细胞反应。